The price drops have stirred interest in whether the direct-to-consumer model might help bring down the country's high drug costs, as it makes pricing less opaque and squeezes out "pharmacy benefit managers", or PBMs, who negotiate drug prices between manufacturers and health insurance plans
Whether youre using a GLP-1, considering it, or trying to understand your options in a weight-focused world, Im here to help you navigate it with care, curiosity, and evidence-based guidance
Article PubMed Google Scholar Aviles-Olmos, I
About 10.3% of patients on the 36 mg dose stopped the drug because of side effects, compared with 2.6% on placebo
Together, we will delve into the role of diet, exercise, and medication adherence, as well as discuss how to tailor our approaches to see meaningful change
WO-2025166413-A1